Does prasugrel achieve superior platelet inhibition when compared with clopidogrel in patients with CAD?

摘要

Clopidogrel in combination with aspirin reduces the number of events related to percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD), and is the recommended standard of care in these patients. Recent studies, however, have shown a marked variability in clopidogrel's ability to inhibit platelet formation, and a substantial number of patients (11-34%) are considered to be nonresponders. Preclinical studies have shown that prasugrel, a new thienopyridine derivative, is around 10 times more potent than clopidogrel. Early clinical studies of patients undergoing PCI have demonstrated low and similar rates of bleeding for prasugrel when compared with clopidogrel.